All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

Following the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the Lymphoma Hub spoke with John C. Byrd, OSUCCC −The James, Columbus, US. We asked, Is acalabrutinib superior to ibrutinib for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?

Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?

Byrd outlines data from the phase III ELEVATE-RR trial, a non-inferiority study which was the first to compare safety and overall survival between the BTK inhibitors acalabrutinib and ibrutinib, in patients with previously treated CLL.